Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q1 2015 (← Previous) (Next →)

Filing Date: May 11, 2015

Total Value ($000): $231,250 (100.0% shares, 0.0% debt)

Holdings (7)

— Juno Therapeutics 36.1%

Value ($000) $83,407 Shares 1,375,000 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 28.9%

Value ($000) $66,861 Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Egalet 14.8%

Value ($000) $34,207 Shares 2,645,558 Est. Cost $5.69 Unrealized —

— FibroGen 13.2%

Value ($000) $30,506 Shares 972,175 Est. Cost $27.34 Unrealized —

— Dicerna Pharmaceuticals 3.7%

Value ($000) $8,661 Shares 360,447 Est. Cost $16.47 Unrealized —

— Achaogen 2.0%

Value ($000) $4,701 Shares 481,694 Est. Cost $13.05 Unrealized —

— Proteon Therapeutics 1.3%

Value ($000) $2,907 Shares 250,000 Est. Cost $10.40 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,375,000	$83,407	36.1%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,138,872	$66,861	28.9%	$38.55	—	Common Stock	699374302
—	Egalet	2,645,558	$34,207	14.8%	$5.69	—	Common Stock	28226B104
—	FibroGen	972,175	$30,506	13.2%	$27.34	—	Common Stock	31572Q808
—	Dicerna Pharmaceuticals	360,447	$8,661	3.7%	$16.47	—	Common Stock	253031108
—	Achaogen	481,694	$4,701	2.0%	$13.05	—	Common Stock	004449104
—	Proteon Therapeutics	250,000	$2,907	1.3%	$10.40	—	Common Stock	74371L109